Biocon’s APIs, generic formulations biz posts ₹578 cr revenues
April 29, 2021
Company faced pricing pressure in the US, travel restrictions delayed approvals & launch new products
Biocon’s active pharma ingredients (APIs) and generic formulations business has posted revenues of ₹578 crore for the fourth-quarter (Q4) of FY 2020-21, a 3 per cent growth compared with ₹562 crore revenues posted last year.
Siddharth Mittal, CEO & Managing Director, Biocon Limited, said, “The FY21 performance was in line with our expectations. Revenues grew by 6 per cent over the previous year, with a profit before tax of 13 per cent, supported by double digit growth in generic formulations and a modest single digit growth in APIs. I am pleased that we were able to ensure continuity of our business operations and serve patients and partners through a challenging year.”
biocon: Biocon rises 3% as co enters Brazilian generic formulation market
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Biocon partners with Libbs Farmaceutica to launch generic drugs in Brazil
indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Biocon enters Latin American market with its generic drugs
freepressjournal.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from freepressjournal.in Daily Mail and Mail on Sunday newspapers.
Biocon Q3 net profit falls 17% to Rs 169 crore, revenue up 7%
The biosimilars and research services segment posted 11 per cent and 13 per cent growth, respectively, in their income during the quarter, while the generics business recorded a 3 per cent decline
BusinessToday.In | January 22, 2021 | Updated 17:39 IST
Biocon Executive Chairperson Kiran Mazumdar-Shaw
Biocon Ltd on Thursday reported a 17 per cent decline in consolidated net profit for October-December quarter of the ongoing financial year at Rs 169 crore. The company had posted a net profit of Rs 203 crore in the year-ago quarter.
However, its revenue rose 7 per cent to Rs 1,879 crore during the quarter ended December, led by double-digit growth in research services and biosimilars business segments.